Lord, Abbett & Co
AXSM icon

Lord, Abbett & Co’s Axsome Therapeutics AXSM Stock Holding History

Lord, Abbett & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Buy
+73,978
New +$16M 0.05% 313

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Lord, Abbett & Co's AXSM Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 73,978 shares worth $18.1M. The stake represents 0.05% of the portfolio and ranks #313 among its holdings.

504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Lord, Abbett & Co held 73,978 shares of Axsome Therapeutics worth $18.1M as of Q2 2026.
  • Axsome Therapeutics was a new Lord, Abbett & Co position in Q2 2026.
  • Axsome Therapeutics made up 0.05% of Lord, Abbett & Co's portfolio in Q2 2026, its #313 holding.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.